# Sorafenib and Letrozole, Anastrozole, or Exemestane in Treating Postmenopausal Women With Estrogen Receptor-Positive and/or Progesterone Receptor-Positive Metastatic Breast Cancer

> **NCT00573755** · PHASE2 · TERMINATED · sponsor: **Mayo Clinic** · enrollment: 4 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** anastrozole
- **DRUG:** exemestane
- **DRUG:** letrozole
- **DRUG:** sorafenib tosylate
- **OTHER:** placebo

## Key facts

- **NCT ID:** NCT00573755
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-12
- **Primary completion:** 2013-04
- **Final completion:** 2013-04
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** lack of participant accrual
- **Last updated:** 2016-02-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00573755

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00573755, "Sorafenib and Letrozole, Anastrozole, or Exemestane in Treating Postmenopausal Women With Estrogen Receptor-Positive and/or Progesterone Receptor-Positive Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00573755. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*